US2012015434A1PendingUtilityA1
Expansion of nk cells and therapeutic uses thereof
Est. expiryNov 4, 2024(expired)· nominal 20-yr term from priority
C07K 2319/32C07K 16/2878A61P 35/00C07K 16/2866C12N 2501/23C07K 14/70578C12N 2502/99A61P 35/02C12N 2502/11C07K 14/47C07K 14/70517C07K 16/2896A61K 39/395C07K 14/7051A61K 40/4211A61K 40/31A61K 40/15A61K 2239/48A61K 2239/22C12N 5/0646
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to novel methods for preferentially activating and expanding NK cells. The methods utilize the stimulatory effects of IL-15 and CD137 ligand to preferentially expand and activate NK cells in a mixed cell culture comprising NK cells.
Claims
exact text as granted — not AI-modified1 . A modified cell line comprising cells that lack major histocompatability complex I molecules wherein said cells are genetically modified to express membrane bound interleukin-15 and a co-stimulatory factor ligand CD137L, where said modified cell line activates natural killer (NK) cells and fail to activate T lymphocytes.
Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.